nach oben

International Journal of Clinical Oncology

Erschienen in:

07.07.2023 | Special Article

Chapter 4: CKD treatment in cancer survivors, from Clinical Practice Guidelines for the Management of Kidney Injury During Anticancer Drug Therapy 2022

verfasst von: Kenji Ishikura, Kenji Omae, Sho Sasaki, Yugo Shibagaki, Satoko Ichioka, Yusuke Okuda, Kenichiro Koitabashi, Koichi Suyama, Takuro Mizukami, Chihiro Kondoh, Sumio Hirata, Takeshi Matsubara, Junichi Hoshino, Motoko Yanagita

Erschienen in: International Journal of Clinical Oncology | Ausgabe 10/2023

Einloggen, um Zugang zu erhalten

Abstract

Chronic kidney disease (CKD) is one of the most disabling disorders with significant comorbidity and mortality. Incidence and prevalence of CKD in cancer survivors are remarkably high in both adults and pediatric patients. The reasons for this high incidence/prevalence are multifold but kidney damage by cancer itself and cancer treatment (pharmacotherapy/surgery/radiation) are the main reasons. Since cancer survivors commonly have significant comorbidities, risk of cancer recurrence, limited physical function or life expectancy, special attentions should be paid when considering the treatment of CKD and its complications. Especially, shared decision-making should be considered when selecting the renal replacement therapies with as much information/facts/evidence as possible.

Mayer DK, Nasso SF, Earp JA (2017) Defining cancer survivors, their needs, and perspectives on survivorship health care in the USA. Lancet Oncol 18:e11–e18PubMedCrossRef

Matsuoka YJ, Okubo R, Shimizu Y et al (2020) Developing the structure of Japan’s cancer survivorship guidelines using an expert panel and modified Delphi method. J Cancer Surviv 14:273–283PubMedCrossRef

Ministry of Health, Labour and Welfare in Japan (2021) Summary of Vital Statistics—Trends in leading causes of death. https://www.mhlw.go.jp/english/database/db-hw/populate/dl/E03.pdf. Accessed 3 March 2023

National Cancer Center in Japan (2007) Cancer Statistics in Japan ‘07—Cancer Prevalence Estimates (in Japanese). https://ganjoho.jp/data/reg_stat/statistics/brochure/2007/FIG21.PDF. Accessed 3 March 2023

Bluethmann SM, Mariotto AB, Rowland JH (2016) Anticipating the ‘Silver Tsunami’: prevalence trajectories and co-morbidity burden among older cancer survivors in the United States. Cancer Epidemiol Biomarkers Prev 25:1029–1036PubMedPubMedCentralCrossRef

Cortaredona S, Ventelou B (2017) The extra cost of comorbidity: multiple illnesses and the economic burden of non-communicable diseases. BMC Med 15:216PubMedPubMedCentralCrossRef

Essa H, Dobson R, Wright D et al (2020) Hypertension management in cardio-oncology. J Hum Hypertens 34:673–681PubMedPubMedCentralCrossRef

Muto S, Matsubara T, Inoue T et al (2023) Chapter 1: Evaluation of kidney function in patients undergoing anticancer drug therapy, from clinical practice guidelines for the management of kidney injury during anticancer drug therapy 2022. Int J Clin Oncol. https://doi.org/10.1007/s10147-023-02372-4

Rosner MH, Jhaveri KD, McMahon BA et al (2021) Onconephrology: the intersections between the kidney and cancer. CA Cancer J Clin 71:47–77PubMedCrossRef

10.

Latcha S, Jaimes EA, Patil S et al (2016) Long-term renal outcomes after cisplatin treatment. Clin J Am Soc Nephrol 11:1173–1179PubMedPubMedCentralCrossRef

11.

Leppert JT, Lamberts RW, Thomas IC et al (2018) Incident CKD after radical or partial nephrectomy. J Am Soc Nephrol 29:207–216PubMedCrossRef

12.

Aguilar Palacios D, Wilson B, Ascha M et al (2021) New baseline renal function after radical or partial nephrectomy: a simple and accurate predictive model. J Urol 205:1310–1320PubMedCrossRef

13.

Tachibana H, Omae K, Ishihara H et al (2022) Validation of predictive model for new baseline renal function after robot-assisted partial nephrectomy or radical nephrectomy in Japanese patients. J Endourol 36:745–751PubMedCrossRef

14.

Naganuma T, Takemoto Y, Maeda S et al (2012) Chronic kidney disease in patients with ileal conduit urinary diversion. Exp Ther Med 4:962–966PubMedPubMedCentralCrossRef

15.

Vejlgaard M, Maibom SL, Stroomberg HV et al (2022) Long-term renal function following radical cystectomy for bladder cancer. Urology 160:147–153PubMedCrossRef

16.

Jiang C, Deng L, Karr MA et al (2022) Chronic comorbid conditions among adult cancer survivors in the United States: results from the National Health Interview Survey, 2002–2018. Cancer 128:828–838PubMedCrossRef

17.

Petrova D, Catena A, Rodríguez-Barranco M et al (2021) Physical comorbidities and depression in recent and long-term adult cancer survivors: NHANES 2007–2018. Cancers (Basel) 13:3368PubMedCrossRef

18.

Shin HY, Linton JA, Shim JY et al (2015) Cancer survivors aged 40 years or elder are associated with high risk of chronic kidney disease: the 2010–2012 Korean National Health and Nutrition Examination Survey. Asian Pac J Cancer Prev 16:1355–1360PubMedCrossRef

19.

Takeuchi M, Shinkawa K, Yanagita M et al (2021) Prevalence, recognition and management of chronic kidney disease in Japan: population-based estimate using a healthcare database with routine health checkup data. Clin Kidney J 14:2197–2202PubMedPubMedCentralCrossRef

20.

Oeffinger KC, Mertens AC, Sklar CA et al (2016) Chronic health conditions in adult survivors of childhood cancer. N Engl J Med. 355:1572–1582CrossRef

21.

Knijnenburg SL, Jaspers MW, van der Pal HJ et al (2012) Renal dysfunction and elevated blood pressure in long-term childhood cancer survivors. Clin J Am Soc Nephrol 7:1416–1427PubMedPubMedCentralCrossRef

22.

Green DM, Wang M, Krasin M et al (2021) Kidney function after treatment for childhood cancer: a report from the St. Jude Lifetime Cohort Study. J Am Soc Nephrol 32:983–993PubMedPubMedCentralCrossRef

23.

McMahon KR, Harel-Sterling M, Pizzi M et al (2018) Long-term renal follow-up of children treated with cisplatin, carboplatin, or ifosfamide: a pilot study. Pediatr Nephrol 33:2311–2320PubMedCrossRef

24.

McMahon KR, Rassekh SR, Schultz KR et al (2020) Epidemiologic characteristics of acute kidney injury during cisplatin infusions in children treated for cancer. JAMA Netw Open. 3:e203639PubMedPubMedCentralCrossRef

25.

Dekkers IA, Blijdorp K, Cransberg K et al (2013) Long-term nephrotoxicity in adult survivors of childhood cancer. Clin J Am Soc Nephrol 8:922–929PubMedPubMedCentralCrossRef

26.

Skinner R, Pearson AD, English MW et al (1998) Cisplatin dose rate as a risk factor for nephrotoxicity in children. Br J Cancer 77:1677–1682PubMedPubMedCentralCrossRef

27.

Skinner R, Parry A, Price L et al (2009) Persistent nephrotoxicity during 10-year follow-up after cisplatin or carboplatin treatment in childhood: relevance of age and dose as risk factors. Eur J Cancer 45:3213–3219PubMedCrossRef

28.

Skinner R, Cotterill SJ, Stevens MC (2000) Risk factors for nephrotoxicity after ifosfamide treatment in children: a UKCCSG Late Effects Group study. United Kingdom Children’s Cancer Study Group. Br J Cancer 82:1636–1645PubMedPubMedCentral

29.

Nada A, Jetton JG (2022) Pediatric onco-nephrology: time to spread the Word-Part II: long-term kidney outcomes in survivors of childhood malignancy and malignancy after kidney transplant. Pediatr Nephrol 37:1285–1300PubMedCrossRef

30.

Mulder RL, Knijnenburg SL, Geskus RB et al (2013) Glomerular function time trends in long-term survivors of childhood cancer: a longitudinal study. Cancer Epidemiol Biomarkers Prev 22:1736–1746PubMedCrossRef

31.

Interiano RB, Delos Santos N, Huang S et al (2015) Renal function in survivors of nonsyndromic Wilms tumor treated with unilateral radical nephrectomy. Cancer 121:2449–2456PubMedCrossRef

32.

Cohen EP, Pais P, Moulder JE (2010) Chronic kidney disease after hematopoietic stem cell transplantation. Semin Nephrol 30:627–634PubMedPubMedCentralCrossRef

33.

Bolling T, Willich N, Ernst I (2010) Late effects of abdominal irradiation in children: a review of the literature. Anticancer Res 30:227–231PubMed

34.

35.

Chao C, Bhatia S, Xu L et al (2020) Chronic comorbidities among survivors of adolescent and young adult cancer. J Clin Oncol 38:3161–3174PubMedPubMedCentralCrossRef

36.

Japanese Society of Nephrology (2018) Evidence-based Clinical Practice Guidelines for the treatment of CKD (in Japanese). https://jsn.or.jp/medic/guideline/. Accessed May 2023

37.

Rowland JH, Bellizzi KM (2014) Cancer survivorship issues: life after treatment and implications for an aging population. J Clin Oncol 32:2662–2668PubMedPubMedCentralCrossRef

38.

Henderson TO, Ness KK, Cohen HJ (2014) Accelerated aging among cancer survivors: from pediatrics to geriatrics. Am Soc Clin Oncol Educ Book e423–e430

39.

Hanahan D, Weinberg RA (2000) The hallmarks of cancer. Cell 100:57–70PubMedCrossRef

40.

Guida JL, Ahles TM, Belsky D et al (2019) Measuring aging and identifying aging phenotypes in cancer survivors. J Natl Cancer Inst 111:1245–1254PubMedPubMedCentralCrossRef

41.

Caan BJ, Cespedes Feliciano EM, Prado CM et al (2018) Association of muscle and adiposity measured by computed tomography with survival in patients with nonmetastatic breast cancer. JAMA Oncol 4:798–804PubMedPubMedCentralCrossRef

42.

Cespedes Feliciano EM, Kroenke C et al (2017) Association of systemic inflammation and sarcopenia with survival in nonmetastatic colorectal cancer: Results from the C SCANS Study. JAMA Oncol 3:e172319PubMedCentralCrossRef

43.

Hsu CY, Chinchilli VM, Coca S et al (2020) Post-acute kidney injury proteinuria and subsequent kidney disease progression; The Assessment, Serial Evaluation, and Subsequent Sequelae in Acute Kidney Injury (ASSESS-AKI) Study. JAMA Intern Med 180:402–410PubMedPubMedCentralCrossRef

44.

Uchida D, Kawarazaki H, Shibagaki Y et al (2015) Underestimating chronic kidney disease without serum creatinine as a screening tool in the general Japanese population. Clin Exp Nephrol 19:474–480PubMedCrossRef

45.

Inker LA, Astor BC, Fox CH et al (2014) KDOQI US commentary on the 2012 KDIGO clinical practice guideline for the evaluation and management of CKD. Am J Kidney Dis 63:713–735PubMedCrossRef

46.

Uhlig K, Boyd C (2011) Guideline for the older adult with CKD. Am J Kidney Dis 58:162–165PubMedCrossRef

47.

Saver JL, Lewis RJ (2019) Number needed to treat: conveying the likelihood of a therapeutic effect. JAMA 321:798–799PubMedCrossRef

48.

The SPRINT Research Group (2015) A randomized trial of intensive versus standard blood-pressure control. N Engl J Med 373:2103–2116PubMedCentralCrossRef

49.

Working Group for Dietary Therapy in CKD with Sarcopenia/frailty (in Japanese) (2019) Recommendation for dietary therapy in predialysis CKD with sarcopenia/frailty. J Jpn Soc Nephrol 61:525–556

50.

Neuen BL, Ohkuma T, Neal B et al (2019) Effect of canagliflozin on renal and cardiovascular outcomes across different levels of albuminuria: data from the CANVAS program. J Am Soc Nephrol 30:2229–2242PubMedPubMedCentralCrossRef

51.

Chinnadurai R, Flanagan E, Jayson GC et al (2019) Cancer patterns and association with mortality and renal outcomes in non- dialysis dependent chronic kidney disease: a matched cohort study. BMC Nephrol 20:380PubMedPubMedCentralCrossRef

52.

Arnold M, Rutherford MJ, Bardot A et al (2019) Progress in cancer survival, mortality, and incidence in seven high-income countries 1995–2014 (ICBP SURVMARK-2): a population-based study. Lancet Oncol 20:1493–1505PubMedPubMedCentralCrossRef

53.

Brattström C, Granath F, Edgren G et al (2013) Overall and cause-specific mortality in transplant recipients with a pretransplantation cancer history. Transplantation 96:297–305PubMedCrossRef

54.

Boissier R, Hevia V, Bruins HM et al (2018) The risk of tumour recurrence in patients undergoing renal transplantation for end-stage renal disease after previous treatment for a urological cancer: a systematic review. Eur Urol 73:94–108PubMedCrossRef

55.

Kasiske BL, Cangro CB, Hariharan S et al (2001) The evaluation of renal transplantation candidates: clinical practice guidelines. Am J Transplant 1(Suppl 2):3–95PubMed

56.

Knoll G, Cockfield S, Blydt-Hansen T et al (2005) Canadian Society of Transplantation: consensus guidelines on eligibility for kidney transplantation. CMAJ 173(10):S1–S25PubMedPubMedCentralCrossRef

57.

European Renal Best Practice Transplantation Guideline Development Group (2013) ERBP guideline on the management and evaluation of the kidney donor and recipient. Nephrol Dial Transplant 28(Suppl 2):ii1–ii71

58.

Campbell S, Pilmore H, Gracey D et al (2013) KHA-CARI guideline: recipient assessment for transplantation. Nephrology 18:455–462PubMedCrossRef

59.

Sprangers B, Nair V, Launay-Vacher V et al (2018) Risk factors associated with post-kidney transplant malignancies: an article from the Cancer-Kidney International Network. Clin Kidney J 11:315–329PubMedCrossRef

60.

Penn I, Hammond W, Brettschneider L et al (1969) Malignant lymphomas in transplantation patients. Transplant Proc 1:106–112PubMedPubMedCentral

61.

Jeong S, Lee HS, Kong SG et al (2020) Incidence of malignancy and related mortality after kidney transplantation: a nationwide, population-based cohort study in Korea. Sci Rep 10:21398PubMedPubMedCentralCrossRef

62.

Vajdic CM, McDonald SP, McCredie MR et al (2006) Cancer incidence before and after kidney transplantation. JAMA 296:2823–2831PubMedCrossRef

63.

Imamura R, Nakazawa S, Yamanaka K et al (2021) Cumulative cancer incidence and mortality after kidney transplantation in Japan: a long-term multicenter cohort study. Cancer Med 10:2205–2215PubMedCrossRef

64.

Blosser CD, Haber G, Engels EA (2021) Changes in cancer incidence and outcomes among kidney transplant recipients in the United States over a thirty-year period. Kidney Int 99:1430–1438PubMedCrossRef

65.

Butler AM, Olshan AF, Kshirsagar AV et al (2015) Cancer incidence among US Medicare ESRD patients receiving hemodialysis, 1996–2009. Am J Kidney Dis 65:763–772PubMedPubMedCentralCrossRef

66.

Cheung CY, Chan GC, Chan SK et al (2016) Cancer incidence and mortality in chronic dialysis population: a multicenter cohort study. Am J Nephrol 43:153–159PubMedCrossRef

67.

Malachi T, Zevin D, Gafter U et al (1993) DNA repair and recovery of RNA synthesis in uremic patients. Kidney Int 44:385–389PubMedCrossRef

68.

Rangel-López A, Paniagua-Medina ME, Urbán-Reyes M et al (2013) Genetic damage in patients with chronic kidney disease, peritoneal dialysis and haemodialysis: a comparative study. Mutagenesis 28:219–225PubMedPubMedCentralCrossRef

69.

Akizawa T, Kinugasa E, Koshikawa S (1994) Increased risk of malignancy and blood-membrane interactions in uraemic patients. Nephrol Dial Transplant 9(Suppl 2):162–164PubMed

70.

Japanese Society for Dialysis Therapy (2021) Current status of dialysis therapy of Japan (as of Dec 31, 2020) (in Japanese). https://docs.jsdt.or.jp/overview/index2021.html. Accessed May 2023

Titel: Chapter 4: CKD treatment in cancer survivors, from Clinical Practice Guidelines for the Management of Kidney Injury During Anticancer Drug Therapy 2022
verfasst von: Kenji Ishikura
Kenji Omae
Sho Sasaki
Yugo Shibagaki
Satoko Ichioka
Yusuke Okuda
Kenichiro Koitabashi
Koichi Suyama
Takuro Mizukami
Chihiro Kondoh
Sumio Hirata
Takeshi Matsubara
Junichi Hoshino
Motoko Yanagita
Publikationsdatum: 07.07.2023
Verlag: Springer Nature Singapore
Erschienen in: International Journal of Clinical Oncology / Ausgabe 10/2023
Print ISSN: 1341-9625
Elektronische ISSN: 1437-7772
DOI: https://doi.org/10.1007/s10147-023-02375-1

Springer Medizin

Chapter 4: CKD treatment in cancer survivors, from Clinical Practice Guidelines for the Management of Kidney Injury During Anticancer Drug Therapy 2022

Abstract

Neu im Fachgebiet Onkologie

Labor, CT-Anthropometrie zeigen Risiko für Pankreaskrebs

Viel pflanzliche Nahrung, seltener Prostata-Ca.-Progression

Alter verschlechtert Prognose bei Endometriumkarzinom

Darf man die Behandlung eines Neonazis ablehnen?

Update Onkologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 10/2023

Ovarian serous borderline tumors with recurrent or extraovarian lesions: a Japanese, retrospective, multi-institutional, population-based study

Acid suppressants reduce the therapeutic effect of immune checkpoint inhibitors and increase the risk of acute kidney injury: a meta-analysis

Correction to: First-line nivolumab plus ipilimumab in metastatic non-small cell lung cancer: 5-year outcomes in Japanese patients from CheckMate 227 Part 1

Clinical significance of intraperitoneal paclitaxel combined with systemic chemotherapy for gastric cancer with peritoneal metastasis

Retrospective study of the efficacy and safety of docetaxel/carboplatin combination therapy as postoperative adjuvant chemotherapy for nonsquamous cell carcinoma of the cervix

Clinical significance of metastatic tumor deposit foci in rectal cancer in the lateral pelvic lymph node area

Neu im Fachgebiet Onkologie

Labor, CT-Anthropometrie zeigen Risiko für Pankreaskrebs

Viel pflanzliche Nahrung, seltener Prostata-Ca.-Progression

Alter verschlechtert Prognose bei Endometriumkarzinom

Darf man die Behandlung eines Neonazis ablehnen?

Update Onkologie